NCT01628965View on ClinicalTrials.gov

A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
Parkinson's Disease
Interventions
DRUG

SPM 962

SPM 962 transdermal patch once a daily up to 36.0 mg/day

Trial Locations (7)

Unknown

Chubu Region

Hokkaido Region

Kanto Region

Kinki Region

Kyushu Region

Shikoku Region

Tohoku Region

Sponsors
All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY